T1	Participants 537 576	1075 patients less than 60 years of age
T2	Participants 300 457	all-trans retinoic acid (ATRA) to chemotherapy for younger patients with nonacute promyelocytic acute myeloid leukemia and high-risk myelodysplastic syndrome
